Inactive Instrument

Highlights Alliqua Biomedical Inc Nasdaq

Equities

Adynxx, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2019	19-11-14	CI
Adynxx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2019	19-08-14	CI
Adynxx, Inc. completed the acquisition of Alliqua BioMedical, Inc. in a reverse merger transaction.	19-05-02	CI
Adynxx Provides Clinical Updates	19-04-22	CI
Adynxx and twoXAR Form Collaboration to Discover and Develop Treatments for Endometriosis	18-11-15	CI
Adynxx, Inc. entered into a definitive merger agreement to acquire Alliqua BioMedical, Inc. in a reverse merger transaction.	18-10-11	CI
Adynxx Completes Enrollment in ADYX-004, a Phase 2 Study of Brivoligide	17-10-04	CI
Adynxx, Inc. Initiates ADYX-004, a Phase 2 Study of AYX1, Lead Compound for the Treatment of Post-Surgical Pain	17-03-01	CI
Adynxx Reports Positive Results for Phase 2b Study of AYX1	15-08-11	CI
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1	14-07-16	CI
Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of its Lead Product Candidate AYX1	13-09-05	CI
Adynxx, Inc. Doses First Patient in Investigational AYX1 Phase 2 Study	13-02-26	CI
Adynxx, Inc. Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain	12-08-07	CI

No results for this search